CoChat

FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease

Deisseroth, Albert, Ko, Chia-Wen, Nie, Lei, Zirkelbach, Jeanne F., Zhao, Liang, Bullock, Julie, Mehrotra, Nitin, Del Valle, Pedro, Saber, Haleh, Sheth, Christopher, Gehrke, Brenda, Justice, Robert, Farrell, Ann, Pazdur, Richard · 2015 · Clinical Cancer Research
Cited by 105

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. The approval was primarily based on the results of a randomized, double-blind trial in which 79 symptomatic patients with MCD were allocated (2:1) to siltuximab plus best supportive care (BSC) or to placebo plus BSC. The primary efficacy endpoint was the proportion of patients in each arm achieving a durable tumor and symptomatic response that persisted for a minimum of 18 weeks without treatment failure. Tumor response was based on independent review of CT scans using the revised Response Criteria for Malignant Lymphoma, and symptomatic response was defined as complete resolution or stabilization of 34 MCD-related signs and symptoms as reported by the investigator. Thirty-four percent of patients in the siltuximab arm and no patients in the placebo arm met the primary endpoint (P = 0.0012). The most common adverse reactions (>10% compared with placebo) during treatment with siltuximab were pruritus, increased weight, rash, hyperuricemia, and upper respiratory tract infection. Clin Cancer Res; 21(5); 950–4. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1678

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 105

Metadata

Authors
Deisseroth, A., Ko, C.-W., Nie, L., Zirkelbach, J. F., Zhao, L., Bullock, J., Mehrotra, N., Del Valle, P., Saber, H., Sheth, C., Gehrke, B., Justice, R., Farrell, A., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2015-03-01
Volume
21
Issue
5
Pages
950-954
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2169461745
Cited by
105
References
2
FWCI
5.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1678
The paper
Deisseroth, A., Ko, C.-W., Nie, L., Zirkelbach, J. F., Zhao, L., Bullock, J., Mehrotra, N., Del Valle, P., Saber, H., Sheth, C., Gehrke, B., Justice, R., Farrell, A., & Pazdur, R. (2015). FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1678

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.